tiprankstipranks
Trending News
More News >

Clover Biopharmaceuticals Faces Arbitration Over $224 Million Claim

Story Highlights
Clover Biopharmaceuticals Faces Arbitration Over $224 Million Claim

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Clover Biopharmaceuticals Ltd. ( (HK:2197) ).

Clover Biopharmaceuticals Ltd. announced that it has received an arbitration request from Gavi, seeking repayment of $224 million in advance payment amounts. Clover believes the claim is without merit and intends to defend itself vigorously, while continuing its development of the RSV vaccine candidate SCB-1019.

More about Clover Biopharmaceuticals Ltd.

Clover Biopharmaceuticals Ltd. operates in the biopharmaceutical industry, focusing on the development of vaccines. The company is advancing its proprietary RSV vaccine candidate SCB-1019 for use in RSV re-vaccination settings and as part of a respiratory combination vaccine.

Average Trading Volume: 1,363,709

Technical Sentiment Signal: Hold

Current Market Cap: HK$319.1M

See more insights into 2197 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1